The effect of zidovudine dose on the formation of intracellular phosphorylated metabolites

AIDS

Volumn 10, Issue 12, 1996, Pages 1361-1367

  Barry, Michael G ^c   Khoo, Saye H ^c   Veal, Gareth J ^c   Hoggard, Patrick G ^c   Gibbons, Sara E ^c   Wilkins, Edmund G L ^a   Williams, Olwen ^b   Breckenridge, Alasdair M ^c   Back, David J ^c  

^a NORTH MANCHESTER GENERAL HOSPITAL   (United Kingdom)

^b GLAN CLWYD HOSPITAL   (United Kingdom)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Antiviral therapy; HIV infection; Zidovudine phosphorylation

Indexed keywords

ACICLOVIR; COTRIMOXAZOLE; DOSULEPIN; DRUG METABOLITE; FLUCONAZOLE; RANITIDINE; TEMAZEPAM; ZIDOVUDINE; ZIDOVUDINE 5' TRIPHOSPHATE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG METABOLISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MONONUCLEAR CELL; NONHUMAN; ORAL DRUG ADMINISTRATION; PHOSPHORYLATION; PRIORITY JOURNAL; RADIOIMMUNOASSAY; VIRUS REPLICATION;

EID: 0029768927     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199610000-00008     Document Type: Article

References (26)

1. Montaner JSG, Schechter MT: A year of transformation in HIV/AIDS. Lancet 1995, 346 (suppl):12.
2. Fischl MA, Richman DD, Grieco MH, et al.: The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. N Engl J Med 1987, 317:185-191.
3. Richman DD, Fischl MA, Grieco MH, et al.: The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. N Engl J Med 1987, 317:192-197.
4. Collier AC, Bozzette S, Coombs RW, et al.: A pilot study of low-dose zidovudine in human immunodeficiency virus infection. N Engl J Med 1990, 323:1015-1021.
5. Norrby SR, Gotzsche PC, Melander H, et al.: Double blind dose response study of zidovudine in AIDS and advanced HIV infection. BMJ 1992, 304:13-17.
6. St Clair MH, Richards CA, Spector T, et al.: 3′-Azido-3′-deoxythymidine triphosphate as an inhibitor and substrate of purified human immunodeficiency virus reverse transcriptase. Antimicrob Agents Chemother 1987, 31:1972-1977.
7. Barry M, Howe JL, Back DJ, et al.: Zidovudine pharmacokinetics in zidovudine-induced bone marrow toxicity. Br J Clin Pharmacol 1994, 37:7-12.
8. Stretcher BN, Pesce AJ, Hurtubise PE, Frame PT: Pharmacokinetics of zidovudine phosphorylation in patients infected with the human immunodeficiency virus. Ther Drug Monit 1992, 14:281-285.
9. Collier AC, Tartaglione T, Corey L: A reduced dose of zidovudine in patients with AIDS. N Engl J Med 1991, 324:994-996.
10. Stretcher BN, Pesce AJ, Frame PT, Greenberg KA, Stein DS: Correlates of zidovudine phosphorylation with markers of HIV disease progression and drug toxicity. AIDS 1994, 8:763-769.
11. Robbins BL, Rodman J, McDonald C, Srinivas RV, Flynn PM, Fridland A: Enzymatic assay for measurement of zidovudine triphosphate in peripheral blood mononuclear cells. Antimicrob Agents Chemother 1994, 38:115-121.
12. Slusher JT, Kuwahara SK, Hamzeh FM, Lewis LD, Kornhauser DM, Lietman PS: Intracellular zidovudine (ZDV) and ZDV phosphates as measured by a validated combined high-pressure liquid chromatography-radioimmunoassay procedure. Antimicrob Agents Chemother 1992, 36:2473-2477.
13. Törnevik Y, Jacobsson B, Britton S, Eriksson S: Intracellular metabolism of 3′-azidothymidine in isolated human peripheral blood mononuclear cells. AIDS Res Hum Retroviruses 1991, 7:751-759.
14. Barry M, Wild M, Veal G, et al.: Zidovudine phosphorylation in HIV-infected patients and seronegative volunteers. AIDS 1994, 8:F1-F5.
15. Veal GJ, Wild MJ, Barry MG, Back DJ: Effects of dideoxyinosine and dideoxycytidine on the intracellular phosphorylation of zidovudine in human mononuclear cells. Br J Clin Pharmacol 1994, 38:323-328.
16. Stretcher BN, Pesce AJ, Frame PT, et al.: Pharmacokinetics of zidovudine phosphorylation in peripheral mononuclear cells from patients infected with human immunodeficiency virus. Antimicrob Agents Chemother 1994, 38:1541-1547.
17. Kuster H, Vogt M, Joos B, et al.: A method for the quantification of intracellular zidovudine nucleotides. J Infect Dis 1991, 164:773-776.
18. Stretcher BN, Pesce AJ, Murray JA, et al.: Concentrations of phosphorylated zidovudine (ZDV) in patient leucocytes do not correlate with ZDV dose or plasma concentration. Ther Drug Monit 1991, 13:335-341.
19. Furman PA, Fyfe JA, St Clair MH, et al.: Phosphorylation of 3′-azido-3′-deoxythymidine and selective interaction of the 5′-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci USA 1986, 83:8333-8337.
20. Hall ET, Yan J-P, Melancon P, et al.: 3′-azido-3′-deoxythymidine potentially inhibits protein glycosylation. J Biol Chem 1994, 269:14355-14358.
21. Van J-P, Ilsley DD, Frohlich C, et al.: 3′-Azidothymidine (zidovudine) inhibits glycosylation and dramatically alters glycosphingolipid synthesis in whole cells at clinically relevant concentrations. J Biol Chem 1995, 270:22836-22841.
22. Törnevik Y, Ullman B, Balzarini J, Wahren B, Eriksson S: Cytotoxicity of 3′-azido-3′-deoxythymidine correlates with 3′-azidothymidine-5′-monophosphate (AZTMP) levels, whereas anti human immunodeficiency virus (HIV) activity correlates with 3′-azidothymidine-5′-triphosphate (AZTTP) levels in cultured CEM T-lymphoblastoid cells. Biochem Pharmacol 1995, 49:829-837.
23. Pluda JM, Mitsuya H, Yarchoan R: Hematological effects of AIDS therapies. Hematol Oncol Clin North Am 1991, 5:229-248.
24. Stretcher BN: Pharmacokinetic optimisation of antiretroviral therapy in patients with HIV infection. Clin Pharmacokinet 1995, 29:46-65.
25. Liliemark J, Peterson C: Pharmacokinetic optimisation of anticancer therapy. Clin Pharmacokinet 1991, 21:213-231.
26. Plunkett W, Gandhi V: Pharmacokinetics of arabinosylcytosine. J Infusion Chemother 1992, 2:167-176.